Atsushi Tanaka

Dr. Atsushi Tanaka

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2024 in The Lancet
Verified
Journal Article
Open access
ATAtsushi Tanaka
Atsushi Tanaka
XMXiong Ma
Xiong Ma
ATAtsushi Takahashi
Atsushi Takahashi
JVJohn M Vierling
John M Vierling
Primary biliary cholangitis is a chronic, autoimmune, cholestatic disease that mainly affects women aged 40-70 years. Recent epidemiological studies have shown an increasing incidence worldwide despite geographical heterogeneity and a decrease in the female-to-male ratio of those the disease affects. Similar to other autoimmune diseases, primary biliary cholangitis occurs in genetically predisposed individuals upon exposure to environmental triggers, specifically xenobiotics, smoking, and the gut microbiome. Notably, the diversity of the intestinal microbiome is diminished in individuals with primary biliary cholangitis. The intricate interplay among immune cells, cytokines, chemokines, and biliary epithelial cells is postulated as the underlying pathogenic mechanism involved in the development and progression of primary biliary cholangitis, and extensive research has been dedicated to comprehending these complex interactions. Following the official approval of obeticholic acid as second-line treatment for patients with an incomplete response or intolerance to ursodeoxycholic acid, clinical trials have indicated that peroxisome proliferator activator receptor agonists are promising additional second-line drugs. Future dual or triple drug regimens might reach a new treatment goal of normalisation of alkaline phosphatase levels, rather than a decrease to less than 1·67 times the upper limit of normal levels, and potentially improve long-term outcomes. Improvement of health-related quality of life with better recognition and care of subjective symptoms, such as pruritus and fatigue, is also an important treatment goal. Promising clinical investigations are underway to alleviate these symptoms. Efforts to facilitate better access to medical care and dissemination of current knowledge should enable diagnosis at an earlier stage of primary biliary cholangitis and ensure access to treatments based on risk stratification for all patients.

1 January 2021 in Clinical and Molecular Hepatology
Verified
Journal Article
Open access
PDF file
ATAtsushi Tanaka
Atsushi Tanaka
Primary biliary cholangitis (PBC) causes chronic and persistent cholestasis in the liver, eventually resulting in cirrhosis and hepatic failure without appropriate treatment. PBC mainly develops in middle-aged women, but it is also common in young women and men. PBC is considered a model of autoimmune disease because of the presence of diseasespecific autoantibodies, that is, antimitochondrial antibodies (AMAs), intense infiltration of mononuclear cells into the bile ducts, and a high prevalence of autoimmune diseases such as comorbidities. Histologically, PBC is characterized by degeneration and necrosis of intrahepatic biliary epithelial cells surrounded by a dense infiltration of mononuclear cells, coined as chronic non-suppurative destructive cholangitis, which leads to destructive changes and the disappearance of small- or medium-sized bile ducts. Since 1990, early diagnosis with the detection of AMAs and introduction of ursodeoxycholic acid as first-line treatment has greatly altered the clinical course of PBC, and liver transplantation-free survival of patients with PBC is now comparable to that of the general population.

1 September 2021 in Journal of Hepatology
Verified
Journal Article
Closed access
ATAtsushi Tanaka
Atsushi Tanaka
JHJunko Hirohara
Junko Hirohara
TNToshiaki Nakano
Toshiaki Nakano
KMKosuke Matsumoto
Kosuke Matsumoto
OCOlivier Chazouillères
Olivier Chazouillères
CCChristophe Corpechot
Christophe Corpechot

4 February 2022 in Hepatology International
Verified
Journal Article
Open access
PDF file
HYHong You
Hong You
XMXiong Ma
Xiong Ma
CECumali Efe
Cumali Efe
GWGui-Qiang Wang
Gui-Qiang Wang
SJSook-Hyang Jeong
Sook-Hyang Jeong
JJJidong Jia
Jidong Jia

28 April 2020 in Hepatology Research
Verified
Journal Article
Closed access
PDF file
ATAtsushi Tanaka
Atsushi Tanaka
DHDrafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology
Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology

1 June 2017 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
ATAtsushi Tanaka
Atsushi Tanaka
STSusumu Tazuma
Susumu Tazuma
KOKazuichi Okazaki
Kazuichi Okazaki
TNTakahiro Nakazawa
Takahiro Nakazawa
KIKazuo Inui
Kazuo Inui
HTHajime Takikawa
Hajime Takikawa